South African (SA) clinical trial has fundamentally transformed the global treatment landscape for drug-resistant tuberculosis (DR-TB), offering a faster, safer, and highly effective cure for patients worldwide.

The BEAT-TB study, which originally launched in Gqeberha in the Eastern Cape to evaluate a shortened treatment regimen, saw its groundbreaking findings published this week in the New England Journal of Medicine.

For decades, surviving drug-resistant TB meant enduring an incredibly grueling and toxic medical journey. Dr Francesca Conradie, from the Clinical HIV Research Unit at Wits University, highlighted the revolutionary shift this discovery marks for patient care.

“In the olden days, when we treated patients with drug-resistant TB, we treated them for 18 months,” Conradie said. “The first six months of that treatment comprised daily injections. Worst of all, that combination of medication only worked half the time, so only 50% of patients were cured. In addition to that, about half of our patients went deaf and lost their hearing, and there were a lot of side effects like nausea and vomiting. It wasn’t very successful.”

The new regimen completely rewrites that narrative, cutting the recovery timeline by two-thirds and dropping the debilitating daily injections entirely.

“Now we are able to treat our patients for only six months,” Dr. Conradie added. “We see it in the numbers too, this treatment cured just under 90% of patients.”

–ChannelAfrica/SABC–